In addition to showing moderate efficacy in trastuzumab-resistant HER2+ BC, ganetespib was able to reverse secondary lapatinib resistance in HER2+ BC cell lines when combined with lapatinib by reducing STAT3-mediated signaling [196]. The gene discussed is STAT3; the disease is breast cancer.